Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Radiother Oncol ; 161: 166-176, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-34146616

RESUMO

BACKGROUND: Radiotherapy reduces in-breast recurrence risk in early breast cancer (EBC) in older women. This benefit may be small and should be balanced against treatment effect and holistic patient assessment. This study described treatment patterns according to fitness and impact on health-related quality-of-life (HRQoL). METHODS: A multicentre, observational study of EBC patients aged ≥ 70 years, undergoing breast-conserving surgery (BCS) or mastectomy, was undertaken. Associations between radiotherapy use, surgery, clinico-pathological parameters, fitness based on geriatric parameters and treatment centre were determined. HRQoL was measured using the European Organisation for the Research and Treatment of Cancer (EORTC) questionnaires. RESULTS: In 2013-2018 2811 women in 56 UK study centres underwent surgery with a median follow-up of 52 months. On multivariable analysis, age and tumour risk predicted radiotherapy use. Among healthier patients (based on geriatric assessments) with high-risk tumours, 534/613 (87.1%) having BCS and 185/341 (54.2%) having mastectomy received radiotherapy. In less fit individuals with low-risk tumours undergoing BCS, 149/207 (72.0%) received radiotherapy. Radiotherapy effects on HRQoL domains, including breast symptoms and fatigue were seen, resolving by 18 months. CONCLUSION: Radiotherapy use in EBC patients ≥ 70 years is affected by age and recurrence risk, whereas geriatric parameters have limited impact regardless of type of surgery. There was geographical variation in treatment, with some fit older women with high-risk tumours not receiving radiotherapy, and some older, low-risk, EBC patients receiving radiotherapy after BCS despite evidence of limited benefit. The impact on HRQoL is transient.


Assuntos
Neoplasias da Mama , Idoso , Neoplasias da Mama/radioterapia , Neoplasias da Mama/cirurgia , Estudos de Coortes , Feminino , Humanos , Mastectomia , Mastectomia Segmentar , Qualidade de Vida , Radioterapia Adjuvante
2.
Int J Stroke ; 16(2): 222-228, 2021 02.
Artigo em Inglês | MEDLINE | ID: mdl-31969072

RESUMO

BACKGROUND AND AIMS: The structured, simplified modified Rankin scale questionnaire (smRSq) may increase reliability over the interrogative approach to scoring the modified Rankin scale (mRS) in acute stroke research and practice. During the conduct of the alteplase-dose arm of the international ENhanced Control of Hypertension ANd Thrombolysis StrokE stuDy (ENCHANTED), we had an opportunity to compare each of these approaches to outcome measurement. METHODS: Baseline demographic data were recorded together with the National Institutes of Health Stroke Scale (NIHSS). Follow-up measures obtained at 90 days included mRS, smRSq, and the 5-Dimension European Quality of life scale (EQ-5D). Agreements between smRSq and mRS were assessed with the Kappa statistic. Multiple logistic regression was used to identify baseline predictors of Day 90 smRSq and mRS scores. Treatment effects, based on Day 90 smRSq/mRS scores, were tested in logistic and ordinal logistic regression models. RESULTS: SmRSq and mRS scores had good agreement (weighted Kappa 0.79, 95% confidence interval (CI) 0.78-0.81), while variables of age, atrial fibrillation, diabetes mellitus, pre-morbid mRS (1 vs. 0), baseline NIHSS scores, and imaging signs of cerebral ischemia, similarly predicted their scores. Odds ratios for death or disability, and ordinal shift, 90-day mRS scores using smRSq were 1.05 (95% CI 0.91-1.20; one-sided P = 0.23 for non-inferiority) and 0.98 (95% CI 0.87-1.11; P = 0.02 for non-inferiority), similar to those using mRS. CONCLUSIONS: This study demonstrates the utility of the smRSq in a large, ethnically diverse clinical trial population. Scoring of the smRSq shows adequate agreement with the standard mRS, thus confirming it is a reliable, valid, and useful alternative measure of functional status after acute ischemic stroke. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01422616.


Assuntos
Isquemia Encefálica , Acidente Vascular Cerebral , Isquemia Encefálica/tratamento farmacológico , Humanos , Qualidade de Vida , Reprodutibilidade dos Testes , Acidente Vascular Cerebral/tratamento farmacológico , Ativador de Plasminogênio Tecidual/uso terapêutico , Resultado do Tratamento
3.
BMJ Open ; 8(3): e020758, 2018 03 27.
Artigo em Inglês | MEDLINE | ID: mdl-29593024

RESUMO

INTRODUCTION: Cerebral autoregulation (CA) is impaired in a multitude of neurological conditions. Increasingly, clinical studies are correlating the nature of this impairment with prognostic markers. In acute intracerebral haemorrhage (ICH), impairment of CA has been associated with worsening clinical outcomes including poorer Glasgow Coma Score and larger haematoma volume. Hypocapnia has been shown to improve CA despite concerns over hypoperfusion and consequent ischaemic risks, and it is therefore hypothesised that hypocapnia (via hyperventilation) in acute ICH may improve CA and consequently clinical outcome. BREATHE-ICH is a CA-targeted interventional study in acute ICH utilising a simple bedside hyperventilatory manoeuvre. METHODS AND ANALYSIS: Patients with acute ICH within 48 hours of onset will be included. The experimental set-up measures cerebral blood flow (cerebral blood velocity, transcranial Doppler), blood pressure (Finometer) and end tidal carbon dioxide (capnography) at baseline, and in response to hypocapnia (-5 mm and -10 mm Hg below baseline) achieved via a 90 s hyperventilatory manoeuvre. Autoregulation is evaluated with transfer function analysis and autoregulatory index calculations. Important classical endpoints associated with this before and after interventional study include death and disability at 14 days and the proportion of recruited individuals able to comply with the full measurement protocol. ETHICS AND DISSEMINATION: A favourable opinion was granted by the East Midlands-Nottingham 1 Research Ethics Committee (17/EM/0283). It is anticipated that the results of this study will be presented at national and international meetings, with reports being published in journals during late 2018. TRIAL REGISTRATION NUMBER: NCT03324321.


Assuntos
Encéfalo/irrigação sanguínea , Exercícios Respiratórios/métodos , Hemorragia Cerebral/complicações , Circulação Cerebrovascular/fisiologia , Homeostase/fisiologia , Doença Aguda , Velocidade do Fluxo Sanguíneo , Encéfalo/fisiopatologia , Estudos de Viabilidade , Feminino , Humanos , Masculino , Projetos de Pesquisa , Resultado do Tratamento
4.
Value Health ; 19(4): 404-12, 2016 06.
Artigo em Inglês | MEDLINE | ID: mdl-27325332

RESUMO

BACKGROUND: Currently in the United Kingdom, the National Health Service (NHS) Breast Screening Programme invites all women for triennial mammography between the ages of 47 and 73 years (the extension to 47-50 and 70-73 years is currently examined as part of a randomized controlled trial). The benefits and harms of screening in women 70 years and older, however, are less well documented. OBJECTIVES: The aim of this study was to examine whether extending screening to women older than 70 years would represent a cost-effective use of NHS resources and to identify the upper age limit at which screening mammography should be extended in England and Wales. METHODS: A mathematical model that allows the impact of screening policies on cancer diagnosis and subsequent management to be assessed was built. The model has two parts: a natural history model of the progression of breast cancer up to discovery and a postdiagnosis model of treatment, recurrence, and survival. The natural history model was calibrated to available data and compared against published literature. The management of breast cancer at diagnosis was taken from registry data and valued using official UK tariffs. RESULTS: The model estimated that screening would lead to overdiagnosis in 6.2% of screen-detected women at the age of 72 years, increasing up to 37.9% at the age of 90 years. Under commonly quoted willingness-to-pay thresholds in the United Kingdom, our study suggests that an extension to screening up to the age of 78 years represents a cost-effective strategy. CONCLUSIONS: This study provides encouraging findings to support the extension of the screening program to older ages and suggests that further extension of the UK NHS Breast Screening Programme up to age 78 years beyond the current upper age limit of 73 years could be potentially cost-effective according to current NHS willingness-to-pay thresholds.


Assuntos
Neoplasias da Mama/economia , Política de Saúde/economia , Mamografia/economia , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Neoplasias da Mama/diagnóstico , Neoplasias da Mama/terapia , Simulação por Computador , Análise Custo-Benefício , Detecção Precoce de Câncer/economia , Inglaterra , Feminino , Humanos , Uso Excessivo dos Serviços de Saúde , Método de Monte Carlo , Qualidade de Vida , Anos de Vida Ajustados por Qualidade de Vida , Medicina Estatal , País de Gales
5.
Ultrasound Med Biol ; 38(6): 997-1003, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22502887

RESUMO

This study aimed to compare the response of metabolic-induced cerebral hemodynamic changes measured using transcranial Doppler (TCD) ultrasonography during passive, active and motor imagery paradigms, and associated peripheral hemodynamic responses. Continuous recordings of bilateral cerebral blood flow velocity (CBFv), blood pressure, heart rate and end-tidal CO(2) were performed in 12 right-handed subjects (aged ≥45 y) before, during and after 60 s of active, passive and mental-imagined paradigms. The results revealed no significant difference in CBFv responses between the paradigms and, furthermore, the temporal patterns of the hemodynamic responses showed some degree of similarity. Moreover, significant changes were seen in cerebral and peripheral hemodynamic responses for all paradigms. Our results suggest that active, passive and motor imagery paradigms can be used interchangeably to assess hemodynamic responses. This will enable more detailed noninvasive assessment in patients, where voluntary movement is not possible, but where abnormalities of cerebral hemodynamic control mechanisms can be anticipated.


Assuntos
Circulação Cerebrovascular/fisiologia , Hemodinâmica/fisiologia , Ultrassonografia Doppler Transcraniana/métodos , Análise de Variância , Velocidade do Fluxo Sanguíneo , Feminino , Humanos , Imaginação/fisiologia , Masculino , Pessoa de Meia-Idade , Movimento/fisiologia
6.
J Neurosci Methods ; 206(2): 143-50, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22366252

RESUMO

Cerebral blood flow velocity (CBFv) changes to sensorimotor and cognitive paradigms have been used to assess the integrity of haemodynamic responses, though the reproducibility of these responses has not been properly assessed. Continuous recordings of blood pressure, end-tidal CO(2), heart rate and bilateral CBFv were obtained during 60s of active, passive and mental imagined paradigms on two different occasions over a 1-week period in 13 healthy subjects. The correlation coefficient, standard error of measurement (SEM), intra-class correlation (ICC) and its 95% CI (confidence intervals) for each variable were calculated at the beginning and end of each paradigm. The temporal patterns of haemodynamic responses revealed substantial reproducibility. For the CBFv response, the SEM ranged from 2.4 to 5.5% for the different manoeuvres, whilst the ICC ranged from 0.5 to 0.8 with better reproducibility occurring at the beginning of the paradigm. These findings have important implications for the design of studies of the natural history of haemodynamic changes following ageing and disease.


Assuntos
Encéfalo/irrigação sanguínea , Circulação Cerebrovascular/fisiologia , Hemodinâmica/fisiologia , Imaginação/fisiologia , Atividade Motora/fisiologia , Idoso , Velocidade do Fluxo Sanguíneo/fisiologia , Pressão Sanguínea/fisiologia , Encéfalo/fisiologia , Feminino , Frequência Cardíaca/fisiologia , Humanos , Masculino , Pessoa de Meia-Idade , Reprodutibilidade dos Testes
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA